首页> 美国卫生研究院文献>other >A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal® Dispersion (NCD) in Patients with Taxane-Refractory Metastatic Castrate-Resistant Prostate Cancer (CRPC)

【2h】

A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal® Dispersion (NCD) in Patients with Taxane-Refractory Metastatic Castrate-Resistant Prostate Cancer (CRPC)

机译：紫杉烷淬火患者2-甲氧基雌二醇（2ME2）纳米晶体®分散体（NCD）的II研究 - 耐紫罗兰转移溶胀的前列腺癌（CRPC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose2ME2 (Panzem^®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-refractory, metastatic CRPC.

著录项

期刊名称 other
作者
Michael R. Harrison; Noah M. Hahn; Roberto Pili; William K. Oh; Hans Hammers; Christopher Sweeney; KyungMann Kim; Scott Perlman; Jamie Arnott; Carolyn Sidor; George Wilding; Glenn Liu;
展开▼
作者单位

展开▼
年(卷),期 -1(29),6
年度 -1
页码 1465–1474
总页数 19
原文格式 PDF
正文语种
中图分类
关键词
Prostate cancer castrate-resistant antiangiogenesis antiproliferative PET scan clinical trials;

机译：前列腺癌;去势抵抗;抗血管生成;抗增殖;PET扫描;临床试验;

相似文献

外文文献
中文文献
专利

1. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). [J] . Harrison MR, Hahn NM, Pili R, Investigational new drugs. . 2011,第6期

机译：在患有紫杉烷类难治性转移去势抵抗性前列腺癌（CRPC）的患者中进行2-甲氧基雌二醇（2ME2）NanoCrystal（R）分散液（NCD）的II期研究。
2. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study [J] . Thakur Manish K., Heilbrun Lance K., Sheng Shijie, Investigational new drugs. . 2016,第1期

机译：ganetespib（一种热休克蛋白90 Hsp90）抑制剂在多西他赛预处理的转移性去势抵抗性前列腺癌（CRPC）患者中的II期试验-前列腺癌临床试验联合会（PCCTC）研究
3. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. [J] . Hahn NM, Zon RT, Yu Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第12期

机译：培美曲塞作为二线化疗用于治疗转移性去势抵抗性前列腺癌（CRPC）的II期研究;印第安纳肿瘤学小组GU03-67。
4. Identification of Circulating Pluripotent Cancer Stem Cells in the Blood of Prostate Cancer Patients for the Diagnosis of Metastatic Cancer [C] . Anette Claudia Schafer, Yawen Ju, Youngbin Tak, International Molecular Medicine Tri-Conference. . 2016

机译：鉴定前列腺癌患者血液中循环多能癌症干细胞诊断转移性癌症
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A phase II trial of ganetespib a heat shock protein 90 Hsp90) inhibitor in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study [O] . Manish K. Thakur, Lance K. Heilbrun, Shijie Sheng, -1

机译：ganetespib（一种热休克蛋白90 Hsp90）抑制剂的II期临床试验在多西他赛预处理的转移性去势抵抗性前列腺癌（CRPC）患者中进行-前列腺癌临床试验联盟（PCCTC）研究
7. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro) [O] . Meulenbeld H.J., van Werkhoven E.D., Coenen J.L.L.M., 2012

机译：荷兰前列腺研究（NePro）对多西他赛联合或不联合利塞膦酸盐用于转移性去势抵抗性前列腺癌（CRPC）患者的随机II / III期研究
8. Targeting Mitochondrial Inhibitors for Metastatic Castrate-Resistant Prostate Cancer. [R] . Denmeade, S. 2017

机译：针对转移性去势抵抗前列腺癌靶向线粒体抑制剂。

A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal® Dispersion (NCD) in Patients with Taxane-Refractory Metastatic Castrate-Resistant Prostate Cancer (CRPC)

摘要

著录项

相似文献

相关主题

期刊订阅